BioSpace News Archive

Orphazyme A/S in restructuring, a late-stage biopharmaceutical company developing arimoclomol for Niemann-Pick disease type C, announces that it has signed an agreement to sell substantially all of the Company’s assets and business activities to KemPharm Denmark A/S, a wholly owned subsidiary of KemPharm Inc.

Zenas BioPharma announced the submission of an investigational new drug application to the China National Medical Products Administration for the initiation of a Phase 1/2 clinical study of ZB001 for the treatment of Thyroid Eye Disease.

Inmagene Biopharmaceuticals announces that the U.S. Food and Drug Administration cleared its investigational new drug application for the drug candidate IMG-004, a non-covalent, reversible, third-generation Bruton Tyrosine Kinase inhibitor, to proceed to the Phase I clinical trial.

KemPharm, Inc. announced a definitive agreement with Orphazyme A/S to acquire arimoclomol, an orally-delivered, first-in-class heat shock protein amplifier being developed as a treatment for Niemann-Pick disease type C.

GeneQuantum Healthcare Co., Ltd. announced that two of the company’s bioconjugate drug candidates have won the approval for clinical trials in Australia, further enhancing GeneQuantum’s pipelines in the clinical stage.

Antengene Corporation Limited announces that its first commercialized product, the oral XPO1 inhibitor XPOVIO® approved for the treatment of relapsed/refractory multiple myeloma, has officially entered multiple hospitals, online-hospitals, and direct-to-patient pharmacies in mainland China.